常用化療劑量

以Cockcroft-Gault計算Ccr(ml/min)時，creatinine最小值為0.7，否則會高估肌酐酸廓清率(Ccr)

Intrathecal therapy (IT)				
TIT	Solu-cortef MTX Ara-C	50 mg (or 100mg) 12 mg 40 mg	(國外用prednisolone 40mg) (國外用MTX 15mg)	特殊: - 可能omit Ara-C -VS黃懷萱 : 12.5mg(¼ amp)
IT Rituximab	Rituximab 1mL=10mg (100mg/10mL; 500mg/50mL)	25 or 30 mg	in preservative-free normal saline 6ml, IT 5min	和systemic rituximab同一天打，註明其餘用於IF

Hodgkin Lymphoma (HL)				
ABVD	Doxorubicin Bleomycin Vinblastine Dacarbazine	25 mg/m^2 10 mg/m^2 6 mg/m^2 375 mg/m^2	D1, D15 D1, D15 D1, D15 D1, D15	因為有Bleomycin(lung fibrosis)，不可同日使用G-CSF，療程中也盡量避免
BEACOPP (括號內為escalated劑量)	Bleomycin Etoposide(esc) Doxorubicin(esc) Cyclophosphamide Vincristine Procarbazine 台灣沒有 Prednisone	10 mg/m^2 100(200) mg/m^2 25(35) mg/m^2 650(1250) mg/m^2 1.4 mg/m^2 100 mg/m^2 (PO) 40 mg/m^2 /day	D8 D1-D3 D1 D1 D8 D1-D7 D1-D14	若ABVD C2後反應不好，建議改打”escalated” BEACOPP Central line highly recommended
BEACOPDac (modified from escalated BEACOPP)	Bleomycin Etoposide Doxorubicin Cyclophosphamide Vincristine Dacarbazine Prednisone	10 mg/m^2 200 mg/m^2 35 mg/m^2 1250 mg/m^2 1.4 mg/m^2 200-250 mg/m^2 40 mg/m^2 /day	D8 D1-D3 D1 D1 D8 D2-D3 D1-D14	Advised from GHSG: B. von Tresckow 比正版esc BEACOPP輕鬆。可以在OPD打，但也有可能FN 參考來源1,2: 建議搭配D9 G-CSF, Valtrex, Baktar Cycle length: 21 d

BrECADD	Brentuximab Etoposide Cyclophosphamide Doxorubicin Dacarbazine Dexamethasone	1.8 mg/kg 150 mg/m^2 1250 mg/m^2 40 mg/m^2 250 mg/m^2 40 mg	D1 D2-4 D2 D2 D3-4 D2-5	效果同BEACOPP Lancet Oncol . 2017 Dec;18(12):1680-1687
BeGEV	Bendamustine Gemcitabine Vinorelbine Prednisolone	90 mg/m^2 800 mg/m^2 20 mg/m^2 100 mg/d	D2, D3 D1, D4 D1 D1-D4	Cycle length: 21 day Need G-CSF D+7起G-CSF可收血球 CR(73%), PR(10%) J Clin Oncol . 2016 Sep 20;34(27):3293-9. .
Pembrolizumab	Pembrolizumab	200 mg	D1	Q3W
Nivolumab	Nivolumab	40 mg or 3 mg/kg	D1	Q2W Lancet Oncol . 2016 Sep;17(9):1283-94
Brentuximab + Nivolumab	Brentuximab Nivolumab	1.8 mg/kg 3 mg/kg	D1 D1	Q3W 3-year PFS 77% Blood . 2021 Aug 12;138(6):427-438
Brentuximab consolidation after auto-HSCT	Brentuximab	1.8 mg/kg	Q3W	Total 16 cycles. Starting from 30-45 days after auto-HSCT. AETHERA trial: 5-y PFS 59% vs 41%
Brentuximab + AVD	Brentuximab Doxorubicin Vinblastine Dacarbazine	1.2 mg/kg 25 mg/m^2 6 mg/m^2 375 mg/m^2	D1, D15 D1, D15 D1, D15 D1, D15	Q4W
Nivo + AVD	Nivolumab Doxorubicin Vinblastine Dacarbazine	40 or 240 mg 25 mg/m^2 6 mg/m^2 375 mg/m^2	Q2W	Alex Francisco Herrera et al., SWOG S1826, a randomized study of ivolumab(N)-AVD versus brentuximab

				vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)..JCO 41, LBA4-LBA4(2023)
Non-Hodgkin's Lymphoma (NHL)				
R-CHOP (or R-CNOP)	**R**ituximab **C**yclophosphamide Doxorubicin(**H**ydroxydaurorubicin) (or Mitoxantrone) Vincristine(**O**ncovin®) **P**rednisolone	375 mg/m^2 750 mg/m^2 50 mg/m^2 (12 mg/m^2) 2 mg 60 mg/m^2 /day	D0 D1 D1 D1 D1 D1-D5	Cycle length: 21
R-CEOP	**R**ituximab **C**yclophosphamide **E**toposide (IF) Vincristine(**O**ncovin®) **P**rednisolone **E**toposide (PO)	375 mg/m^2 750 mg/m^2 50 mg/m^2 2(1.4mg/m^2) mg 60 mg/m^2 /day 100 mg/m^2	D0 D1 D1 D1 D1-D5 D2-3	Cycle length: 21
R-GDP	**R**ituximab Gemcitabine Dexamethasone Cisplatin (Carboplatin)	375 mg/m^2 1000 mg/m^2 20 mg BID 75 mg/m^2 (AUC=5)	D1 (化療前) D1, D8 D1-D4 D1 D1	比R-DHAP毒性低
R-DHAP	**R**ituximab **D**examethasone **H**igh dose **A**ra-C **C**isplatin	375 mg/m^2 40mg 2000 mg/m^2 Q12H 100 mg/m^2	D1 (化療前) D1-D4 D2 (共4000) D1	Steroid D1在R前打。D2分2次20mg在Ara-C前打。 腎毒性Gr3-4約有11%。 若要收血球G-CSF Day 6起打。PBSCH since D10, 11
Modified DHAP	**D**examethasone **H**igh dose **A**ra-C **C**isplatin	40mg IV/PO 2000 mg/m^2 Q12H 25 mg/m^2 cIF	D1-D4 D2 (共4000) D1-D4	Cisplatin改25 mg/m^2 x 4 d。使得腎毒性減少(Gr 3-4 creatinine上升只有2.2%)。若要收血球G-CSF Day 7起打。PBSCH since D10, 11。 原始文章無收錄CNS lymphoma病人，Ara-C劑量分成0.5g Q12H x 4天給，CNS劑量可能不

				夠。在此維持原始DHAP的2g Q12H x 1 day。 參考自J Cancer Res Clin Oncol . 2019 Dec;145(12):3067-3073
VR-DHAP	Bortezomib, **V** **Ri**tuximab **D**examethasone **H**igh dose **A**ra-C **C**isplatin	1.3 mg/m^2 375 mg/m^2 40mg 2000 mg/m^2 Q12H 100 mg/m^2	D1,4,8,11 D1 (化療前) D1-D4 D2 (共4000) D1	若Plt < 50k, 肝功能異常，可考慮Bortezomib只給D1,4 Steroid D1在R前打。D2分2次20mg在Ara-C前打。 若要收血球G-CSF Day 6起打。PBSCH since D10, 11
EPOCH (or EPOCN)	Etoposide Prednisolone Vincristine Cyclophosphamide Doxorubicin (or Mitoxantron)	50 mg/m^2 60 mg/m^2 /day 0.5 mg 750 mg/m^2 10 mg/m^2 3 mg/m^2	D1-D4 D1-D6 D1-D4 D5 D1-D4	
Dose adjusted-EPOCH (or EPOCN)	Etoposide Prednisolone Vincristine Doxorubicin (or Mitoxantron) Cyclophosphamide G-CSF	50 mg/m^2 (混合cIF) 60 mg/m^2 BID 0.5 mg (0.4 mg/m^2, 混合cIF) 10 mg/m^2 (混合cIF) 3 mg/m^2 750 mg/m^2 5 ug/kg	D1-D4 D1-D5 D1-D4 D1-D4 D5 D6-	Etoposide, Vincristine, Doxorubicin泡在一起用CVC給(Cyclophosphamide最後給) Prophylaxis: PPI, Baktar, Laxatives N Engl J Med . 2013 11;368(15):1408-16
	劑量調整原則: • 從Level 1開始 • 若Nadir ANC≧500, 上調一級劑量(20%) • 若1-2次抽血Nadir ANC≦500, 維持上次劑量 • 若Nadir Plt ≦ 25000, 或是3次以上抽血Nadir ANC≦500, 減少一級劑量 • 原始study大部分會用到Level 4 • If diameter reduction > 20% between C4 and C6: treat 6 cycles • If diameter reduction < 20% between C4 and C6: treat 8 cycles			

Drugs	Drug Doses per Dose Levels							
	-2	-1	1	2	3	4	5	6
Doxorubicin (mg/m^2/day)	10	10	10	12	14.4	17.3	20.7	24.8
Etoposide (mg/m^2/day)	50	50	50	60	72	86.4	103.7	124.4
Cyclophosphamide (mg/m^2/day)	480	600	750	900	1080	1296	1555	1866

Figure S3. Drug Dose Levels. The drug dose escalation for doxorubicin, etoposide and cyclophosphamide are shown for each dose level. The doses are escalated 20% above the last cycle. The dose 20% dose escalation is based on the previous doses (i.e. compounded dose escalation). Only cyclophosphamide is adjusted when reducing below level 1.

ESHAP	Etoposide Methylprednisolone Ara-C Cisplatin	40 mg/m^2 280 mg 2000 mg/m^2 25 mg/m^2	D1-D4 D1-D5 D5 D1-D4	**E**toposide **S**olu-Medrol **H**igh-dose **A**ra-C Cis**P**latin
BOMES	BiCNU Vincristine Methotrexate Etoposide Methylprednisolone	65 mg/m^2 2 mg 1500 mg/m ^{2} 50 mg/m^2 200 mg	D1-D2 D1, D8 D7 or D8 or D15 D1-D5 D1-D7	MTX D1 infusion 24 hours -> D3 AM 05:00 開始Rescue MTX D1 infusion 6 hours -> D2 PM 17:00 開始Rescue
FND	Fludarabine Mitoxantrone Dexamethasone	25 mg/m^2 10 mg/m^2 20 mg/m^2 /day	D1-D3 D1 D1-D5	
HDMTX	Methotrexate	8000 mg/m^2 (6hr)	D1	MTX勿和PPI, penicillin併用, 若有effusion請先抽乾 MTX D1 infusion 6 hours -> D2 PM 17:00 開始Rescue
R-HDMTX-Ara-C + ASCT (PCNSL)	Rituximab Methotrexate Cytarabine -- Busulfan Thiotepa	375 mg/m^2 3.5 g/m^2 2 g/m^2 BID -- 3.2 mg/kg IV 5 mg/kg	D0, D4 D1 D2, D3 -- D-7, D-6 D-5, D-4	Cycle length: 21 days PBSCH after C1 2-year PFS/OS 93% Blood Adv (2020) 4 (14): 3378–3381
MT-R x 4 -- then -- EA (consolidation) x 1 (PCNSL)	Rituximab Methotrexate Temozolomide -- Etoposide Cytarabine	375 mg/m^2 8 g/m^2 150 mg/m^2 PO (奇數cycle才吃) -- 10 mg/kg cIF QD (共40mg/kg) 2 g/m^2 Q12H (共16 g/m^2)	D3 (C1-C6 only) D1 D7-D11 -- D1-D4 D1-D4	Cycle length: 14 days. Prophylaxis: Steroid eye drops, G-CSF, FQ, azole, Valtrex, Baktar CR(66%), 2-y-PFS(57%) J Clin Oncol . 2013 Sep 1;31(25):3061-8
CyVE (< 60 y/o) (R/R PCNSL)	Ara-C (Cytarabine) Ara-C (Cytarabine) Etoposide	50 mg/m^2 (12 hours) 2000 mg/m^2 (3 hours) 200 mg/m^2 (2 hours)	D1-D5(台大沒打) D2-D5 D2-D5	Less neurotoxicity 100% ORR, 71% CR Cycle length: 28 D 可接PBSCH, G-CSF 5ug/kg/day since D7

CyVE (> 60 y/o) (R/R PCNSL)	Ara-C (Cytarabine) Ara-C (Cytarabine) Etoposide	50 mg/m^2 (12 hours) 2000 mg/m^2 (3 hours) 150 mg/m^2 (2 hours)	D1-D5(台大沒打) D2-D4 D2-D5	ASCT用Thiotepa-BuCy (Nadir 14 d. 台大套餐打的比這裡寫的弱) Soussain C et al, J. Clin. Oncol. 2008
HDMA	Methotrexate Ara-C --(若要PBSCH)-- G-CSF (Monitor HPC)	3500 mg/m^2 (6hr) 3000 mg/m^2 --(若要PBSCH)-- 10 ug/kg/day	D1 D4-D5 D6起 QN D15起	Transfusion. 2014 Mar;54(3):509-15. MTX勿和PPI, penicillin併用, 若有effusion請先抽乾
R-BAC	Rituximab Bendamustine Ara-C	375 mg/m^2 70 mg/m^2 800 mg/m ^{2}	D0 D1-D2 D1-D3	用於Mantle 2 y PFS: 70-95% Cycle length: 28 D 4-6 cycles 要打G-CSF, FN 12%
BAS	BCNU Ara-C Methylprednisolone	65 mg/m^2 2000 mg/m^2 200 mg	D1, D2 D3 D1-D5	蔡oo貴用這個打 BNS
R-Temozolomide	Rituximab Temozolomide	375 mg/m^2 150 mg/m^2	D1 D1-D5	Every 28 days ORR 26% (6/23) Eur J Cancer . 2004 Jul;40(11):1682-8
R-HDAC (PBSCH) + R-TBC (ASCT) (PCNSL)	Rituximab Cytarabine -- Rituximab Thiotepa Busulfan Cyclophosphamide Mesna	1000 mg/m^2 3000 mg/m^2 Q12H (4 doses) -- 1000 mg/m^2 200-250 mg/m^2 0.8 mg/kg Q6H or 2.7 mg/kg QD 60 mg/kg 15 mg/kg Q6H	D1, D8 D1, D2 -- D-9, D-2 D-9 to D-7 D-6 to D-4 D-3 to D-2 D-3 to D-2	R-TBC: Age > 60 則 Busulfan改為0.6 mg/kg Q6H.(Kate Oxynasarski建議60歲以上不要打TBC) Cancer. 2015 Jan 15;121(2):226-33 Ann Hematol.2025 Jul;104(7):3843-3854
TT-BCNU (ASCT) (PCNSL)	Thiotepa BCNU	5 mg/kg 400 mg/m^2	D-6, D-5 D-4	JAMA Oncol. 2021 Jul 1;7(7):993-1003 (Kate Oxynasarski建議TT要用更大的劑量如 10-20 mg/kg)
Non-Hodgkin's Lymphoma (NHL) (Continued)				
Chlorambucil (regular dose)	Chlorambucil (2mg/tab)	吃法1: 6 mg/m^2 吃法2: 10-12 mg/m^2	D1-D14 D1-D7	Cycle length: 28 days

		吃法3: 10 mg/day	QD Until CR + 3m	可搭類固醇(0.5 mg/kg/day) or Rituximab
Chlorambucil (pulse)	Chlorambucil (2mg/tab)	16 mg/m^2	D1-D5	Cycle length: 28 days 可搭類固醇 or Rituximab
FCR **(< 60 y/o)**	Rituximab Rituximab Fludarabin Cyclophosphamide	375 mg/m^2 500 mg/m^2 25 mg/m^2 /day 250 mg/m^2 /day	D0 (C1) D0 (C2-C6) D1-D3 D1-D3	Cycle length: 28 days Grade III-IV Neutropenia(52%) Rituximab maintenance 500 mg/m^2 Q3M
FCR-Lite **J Clin Oncol. 2009 Feb 1;27(4):498-503**	Rituximab Rituximab Fludarabin Cyclophosphamide	375 mg/m^2 500 mg/m^2 20 mg/m^2 /day 150 mg/m^2 /day	D0 (C1) D0, D14 (C2-C6) D1-D3 D1-D3	Cycle length: 28 days Grade III-IV Neutropenia(13%) Rituximab maintenance 500 mg/m^2 Q3M
R-BACOD-m	Rituximab Bleomycin Adriamycin Cyclophosphamide Vincristine Dexamethasone Methotrexate	375 mg/m^2 4 mg/m^2 45 mg/m^2 600 mg/m^2 2 mg 6 mg/m^2 200 mg/m^2	D0 D1 D1 D1 D1 D1-D5 D8, D15	
R-CODOX-M	Rituximab Cyclophosphamide Vincristine Doxorubicin Methotrexate	375 mg/m^2 800 mg/m^2 200 mg/m^2 2 mg 40 mg/m^2 3000 mg/m^2 IF 24 hours	D0 D1 D2-D5 D1, D8 D1 D10	2010年後打3g/m2
R-IVAC	Rituximab Ifosfamide Etoposide Cytarabine	375 mg/m^2 1500 mg/m^2 QD 60 mg/m^2 QD 2000 mg/m^2 BID	D0 D1-D5 D1-D5 D1-D2	

R-ICE	Rituximab Ifosfamide Mesna (mix with ifosfamide) Carboplatin Etoposide	375 mg/m^2 5000 mg/m^2 cIF 24 hours 5000 mg/m^2 cIF 24 hours AUC= 5 100 mg/m^2	D0 D2 D2 D2 D1-D3	Carboplatin劑量以Calvert formula計算= Target AUC * (Ccr+25). Max: 750 mg/cycle
Waldenström macroglobulinemia (WM)				
BDR ORR(85%), CR(3%), PR(58%) 7-year OS(66%)	Bortezomib(C1) Bortezomib(C2-5) Dexamethasone Rituximab	1.3 mg/m^2 **IV** (原始文章IV use) 1.6 mg/m^2 IV 40 mg/cycle 375 mg/m^2/cycle	D1,4,8,11 D1,8,15,22 D1 D1	Cycle length: 21 days (C1), 35 days (C2-C5) Blood (2017) 129 (4): 456-459
Benda-R	Rituximab Bendamustine	375 mg/m^2 90 mg/m^2	D0 D1-D2	Benda premedications (optional): vena, paramol If ANC < 1000 or Plt < 75000 on D7, reduce Benda from 90-> 70 mg/m^2 or 70-> 50 mg/m^2
DRC ORR(83%), Major response(74%)	Dexamethasone Rituximab Cyclophosphamide	40 mg IF 375 mg/m^2/cycle IF 100 mg/m^2 PO BID	D1 D1 D1-D5	Cycle length: 21 days (沒有RB的選擇) J Clin Oncol 25(22):3344-3349
Diffuse Large B-cell Lymphoma (DLBCL)				
CHOP (or R-CHOP)	Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisolone	375 mg/m^2 750 mg/m^2 50 mg/m^2 2 mg 60 mg/m^2 /day	D0 (共 8 cycles) D1 D1 D1 D1-D5	
R-Gemox	Rituximab Gemcitabine Oxaliplatin	375 mg/m^2 1000 mg/m^2 100 mg/m^2	D0, D14 D1, D15 D1, D15	
NK/T Cell Lymphoma (治癒性RT通常都50-60Gy)				

⅔ DeVIC (搭配CCRT)	Dexamethasone Etoposide Ifosfamide Carboplatin *RT*	40 mg 67 mg/m ^{2} 1000 mg/m ^{2} 200 mg/m ^{2} *50-50.4 Gy*	D1-D3 D1-D3 D1-D3 D1 *5-6 weeks*	G-CSF if WBC < 2000 J Clin Oncol. 2009 Nov 20;27(33):5594-600 Cycle length: 21 d Total 3 cycles 劑量調整: FN: ⅔ of all chemo ≧ 3級血小板低下: ⅔ carboplatin ≧ 2級血尿: ⅔ Ifosfamide WBC< 2k or Plt < 100k: delay至多3w
LOD	L-asparaginase Vincristine Predonine	6000 IU/m^2 (50 IU skin test) 1.4 mg/m^2 100 mg	D1-D5 D1 D1-D5	Cycle length: 21 days LOD(2)→IFRT(56Gy)→LOD(2-4)
SMILE	Dexamethasone Methotrexate Ifosfamide L-asparaginase (pegaspargase) Etoposide	40 mg 2000-3000, ex: 1500mg/m ^{2} 1500 mg/m ^{2} 6000 IU/m ^{2} (2000-2500 IU/m^2) 100 mg/m ^{2}	D2-D4 D1 D2-D4 From D8(QOD x7 doses) D2-D4	G-CSF since D6
GELOX	Gemcitabine Oxaliplatin L-asparaginase	1000(標準)/800 mg/m^2 130(標準)/85 mg/m^2 6000 U/m^2	D1,D8 D1 D1-D7	Cycle length: 21 days 自費:約13000 NTD/cycle
P-GEMOX	Gemcitabine Oxaliplatin Pegaspargase	1000 mg/m^2 130 mg/m^2 2500 IU/m^2	D1, D8 D1 D1 (IM)	Cycle length: 21 days
P-GEMOX	Gemcitabine Oxaliplatin Pegaspargase	1250 mg/m^2 85 mg/m^2 2500 IU/m^2	D1 D1 D1 (IM)	Cycle length: 14 days
	GELOX/P-GEMOX在新診斷ENKTL, stage IE, IIE。搭配RT成sandwich induction處方 GELOX(2)→IFRT(56 Gy/28 fr)→GELOX(2-4)			
DICE-L	Dexamethasone Ifosfamide Cisplatin Etoposide	20 mg/m^2 1.2 g/m^2 25 mg/m^2 60 mg/m^2	D1-D4 D1-D3 D1-D4 D1-D4	Cycle length: 21 days DICE(4)→RT(45Gy) 5-year PFS(82.9%) (會Nadir)

	L-asparaginase	6000 IU/m^2	D6-D11	Leuk Lymphoma. 2016 Jul;57(7):1600-6
DDPG	Dexamethasone Cisplatin Gemcitabine L-asparaginase	15 mg/m^2 20 mg/m^2 800 mg/m^2 6000 IU/m^2 (4 IU skin test)	D1-D5 D1-D4 D1,D8 D1-D7 (SC)	Cycle length: 21 days 過敏可換Pegaspargase 2-year PFS 61.8% Oncotarget. 2016 Aug 23; 7(34): 55721–55731
Pembrolizumab	Pembrolizumab	2 mg/kg	D1	Q3W 5/7 CR after 7 cycles Blood 2017 129:2437-2442
Nivolumab	Nivolumab	40 mg or 3 mg/kg (仿照HL)	D1	Q2W Ann Hematol. 2018 Jan;97(1):193-196
T-cell lymphoma				
Pralatrexate	Folic acid Vitamin B12 Pralatrexate	1-1.25 mg/day PO 1g IM 30 mg/m^2 weekly	Since D-11 Every 8-10 wk QW on W1-W6	Cycle length: 7 weeks (做6休1) 若mucositis嚴重,可補充Leucovorin
Acute Myeloid Leukemia (AML)				
I3A7 (Induction)	Idarubicin Ara-C	12 mg/m^2 100 mg/m^2	D1-D3 D1-D7	
I2A5 (Consolidation)	Idarubicin Ara-C	12 mg/m^2 100 mg/m^2	D1-D2 D1-D5	
Gemtuzumab ozogamacin (Mylotarg)	Gemtuzumab ozogamacin (relapse, monotherapy)	3 mg/m^2 (maximum 4.5 mg/dose)	D1,4,7	Premedication: - Paramol x 1 - Vena x 1 - Solu-medrol (1mg/kg)
Ven+Cladribine +LDAC (induction)	Venetoclax Cladribine Cytarabine	400 mg 5 mg/m^2 IF 2 hrs 20 mg SC BID	D1-21 D1-5 D1-10	J Clin Oncol . 2022 Jun 15;JCO2102823

Ven+Cladribine +LDAC (consolidation_A)	Venetoclax Cladribine Cytarabine	400 mg 5 mg/m^2 IF 2 hrs 20 mg SC BID	D1-21 D1-D3 D1-D10	
Ven+Vidaza (consolidation_B)	Venetoclax Vidaza	400 mg 75 mg/m^2	D1-21 D1-7	
CLIA+ Venetoclax (induction)	Cladribine Cytarabine Idarubicin Venetoclax	5 mg/m^2 IF 2 hrs 1.5 g/m^2 IF 2 hrs(1 g/m^2 in age ≧ 60) 10 mg/m^2 400 mg	D1-5 D1-5 D1-3 D2-8	先Cladribine再滴Cytarabine WBC ≧ 20000/uL要先cytoreduction。 Nadir時搭配anti-bacteria/fungus/virus prophylaxis. Cycle length: 28 days https://doi.org/10.1016/S2352-3026(21)00192-7
CLIA+ Venetoclax (Consolidation)	Cladribine Cytarabine Idarubicin Venetoclax	5 mg/m^2 IF 2 hrs 1.0 g/m^2 IF 2 hrs(0.75 g/m^2 in age ≧ 60) 8 mg/m^2 400 mg	D1-3 D1-3 D1-2 D2-8	
Re-induction for relapse: HiDAC-containing regimen, FLAG, NEC, CLAG				
FLAG (or I3FLAG) (or M2FLAG)	**Fl**udarabine **A**ra-C **G**-CSF (Idarubicin) (Mitoxantrone)	30 mg/m^2 2000 mg/m^2 300 μg 10 mg/m^2 10 mg/m^2	D1-D5 D1-D5 D0-D6 D1-D3 D1-D2	Solu-Medrol 40mg QD(before Ara-C)
HDAC (or I3HDAC) (or N3HDAC)	Ara-C (Idarubicin) (Mitoxantrone)	2000 mg/m^2 (q12h，共8 dose) 12 mg/m^2 12 mg/m^2	D1-D5 D1-D3 D1-D3	
N3A7	Mitoxantrone Ara-C	12 mg/m^2 100 mg/m^2	D1-D3 D1-D7	
NEC (or MEC)	**M**itoxa**N**trone **E**toposide Ara-**C**	8 mg/m^2 100 mg/m^2 400 mg/m^2 (q12h，共10 dose)	D1-D3 D1, D3, D5 D1-D5	
CLAG	**Cl**ofarabine **A**ra-C	30 mg/m^2 500 mg/m^2	D1-D5 D1-D5	Ara-C要在Clofarabine滴完後3.5 hr再給

LDAC	Ara-C	20 mg/m^2	D1-D10	
Frail AML patients				
Venetoclax + LDAC	Venetoclax Ara-C Venetoclax	100mg-200mg-400mg 20 mg/m^2 600 mg/d	D1-D3 D1-D10 D1-D28 (titrate from 50-100mg every 4-5 days)	Blood 2017 130:890 1-y CR/CRi: 62% JCO. 2019 May 20;37(15):1277-1284 Venetoclax dose reduction to 50%(if moderate CYP3A inhibitor) or 25%(if strong CYP3A inhibitor)
Venetoclax + Azacitidine	Venetoclax Azacitidine	100mg-200mg-400mg- 75 mg/m^2	D1-D28 D1-D7	Blood 2018 08:868752 8.9 m CR/CRi: 67% Cycle length: 28 day
Azacitidine + pembrolizumab	Azacitidine Pembrolizumab	125 mg/m^2 2 mg/kg	D1-D5 D1	
Acute Promyelocytic Leukemia (APL)				
APML4 Induction	All-trans retinoic acid Idarubicin ATO Prednisone	45 mg/m^2/day 6-12 mg/m^2 0.15 mg/kg/day IF 1 mg/kg/day PO	D1-D36 D2,4,6,8 D9-D36 D1-D10	Age 1-60 (Ida 12) Age 61-70 (Ida 9) Age >70 (Ida 6) Prednisone until WBC < 1000/uL
	Component therapy: Plt > 30k, normal PT/aPT, fibrinogen > 150 mg/dL If grade III-IV non-hematologic AE(ex: QTc prolong): may reduce to ATRA(25 mg/m^2/d), ATO(0.08 mg/kg/day) *Blood*. 2012 Aug 23;120(8):1570-80			
APML4 Consolidation 1	All-trans retinoic acid ATO	45 mg/m^2/day 0.15 mg/kg/day IF	D1-D28 D1-D28	
APML4 Consolidation 2 (OPD)	All-trans retinoic acid ATO	45 mg/m^2/day 0.15 mg/kg/day IF	D1-7, 15-21, 29-35 D1-5, 8-12, 15-19, 22-26, 29-33	Cycle length: 5 weeks

APML4 Maintenance (OPD)	All-trans retinoic acid MTX 6-MP	45 mg/m^2/day 5-15 mg/m^2/week PO 50-90 mg/m^2/day PO	D1-D14 D15-90 D15-90	Total 8 cycles (2 years) Cycle length: 90 days Target WBC 1-2k/uL
Chronic myelogenous Leukemia (CML)				
	Imatinib	400 mg PO QD		
Acute Lymphoblastic Leukemia (ALL)				
GRAALL 2003 ***Corticosteroid prephase***	Prednisone(oral) Methotrexate(IT)	60 mg/m^2/day 15 mg	D-7 - D-1 D-7 - D-4(挑1天打1次)	台大通常不在這時候做IT，因PB blastosis February 2009Journal of Clinical Oncology 27(6):911-8
GRAALL 2003 ***Induction part 1***	Prednisone(oral) Daunorubicin(IF, 台大用doxorubicin) Vincristine (IV) Asparaginase(IM) Cyclophosphamide(IF) **Rituximab**	60 mg/m^2/day 50 mg/m^2/day 2 mg 6000 units/m^2/day 750 mg/m^2/day 375 mg/m^2/day	D1-D14 D1-D3 D1, D8 D8, D10, D12 D1 D1, D7	Daunorubicin: doxorubicin= 1: **0.6**-1 Asparaginase也可以IV(過敏機會高) or SC Rituximab: 用於 65 歲以下 CD20+ cell > 20% ALL。若不做移植，共需375 mg/m^2 16個dose
GRAALL 2003 ***Induction part 2***	Daunorubicin(IV) Vincristine (IV) Asparaginase(IM) Cyclophosphamide(IV) G-CSF(SC)	30 mg/m^2/day 2 mg 6000 units/m^2/day 750 mg/m^2/day (Good responder) 500 mg/m^2 Q12H (Poor responder) 150 mcg/m^2/day	D1-D2 D1, D8 D6, D8, D10, D12, D14 D1 D1-D2 D3 -	Steroid prephase做完PB blast ≥ 1000/ul or/and induction part 1 D7 BM blast ≥ 5%視為poor responder Asparaginase需先打4 unit做skin test
GRAALL 2003 ***Salvage course*** **(I3HDAC)**	Idarubicin(IF) Cytarabine(IF) **Rituximab**	12 mg/m^2/day 2000 mg/m^2 Q12H 375 mg/m^2/day	D1-D3 D1-D4 D1, D7	Induction part 2 結束後沒有CHR的則進入salvage course
GRAALL 2003 ***Block Ara-C(1)***	Cytarabine(IV) Dexamethasone(PO) Asparaginase(IM) G-CSF(SC) **Rituximab**	2000 mg/m^2 Q12H 10 mg Q12H 10000 units/m^2/day 150 mcg/m^2/day 375 mg/m^2/day	D1-D2 D1-D2 D3 D7-D13 D1	台大用methylprednisolone 40 mg 代替 Dexa 10mg before Cytarabine
GRAALL 2003 ***Block MTX(2)***	Methotrexate(cIF) Leucovorin(IV) Vincristine(IV) Asparaginase(IM)	3000 mg/m^2 cIF 24 hours 15 mg Q6H 2 mg 10000 units/m^2/day	D1 D3 5AM-D4 11PM D1 D2	台大Mercaptopurine用吃的(同劑量)

	Mercaptopurine(IV) G-CSF(SC)	60 mg/m^2/day 150 mcg/m^2/day	D1-D7 D8-D13	Leucovorin用100 mg Q6H
GRAALL 2003 ***Block Endoxan(3)***	Cyclophosphamide(IF) Etoposide(IF) Methotrexate(IF) G-CSF(SC) **Rituximab**	500 mg/m^2/day 75 mg/m^2/day 25 mg/m^2 150 mcg/m^2/day 375 mg/m^2/day	D1-D2 D1-D2 D1 D3 - D1	
GRAALL 2003 ***Late intensification (induction CR)***	Prednisone(oral) Daunorubicin(IF) Vincristine (IV) Asparaginase(IM) Cyclophosphamide(IF) G-CSF(SC) **Rituximab**	60 mg/m^2/day 30 mg/m^2/day 2 mg 6000 units/m^2/day 500 mg/m^2 Q12H 150 mcg/m^2/day 375 mg/m^2/day	D1-D14 D1-D3 D1, D8, D15 D8, D10, D12, D18, D20, D22 D15 If ANC < 500 D1, D7	Between block 6 and 7
GRAALL 2003 ***Late intensification (salvage CR)***	Idarubicin(IF) Cytarabine(IF) G-CSF(SC)	9 mg/m^2/day 2000 mg/m^2 Q12H 150 mcg/m^2/day	D1-D3 D1-D4 D9 -	
GRAALL 2003 ***Maintenance part 1***	Prednisone(oral) Vincristine (IV) Methotrexate(PO) Mercaptopurine(PO) **Rituximab**	40 mg/m^2/day 2 mg 25 mg/m^2/week 60 mg/m^2/day 375 mg/m^2/day	D1-D7 D1 D1,D8,D15,D22 D1-D28 奇數月D1	Cycle length: 28 days Block結束後再維持1年 MTX一星期要吃15顆，怎麼吃好
GRAALL 2003 ***Maintenance part 2***	Methotrexate(PO) Mercaptopurine(PO)	25 mg/m^2 60 mg/m^2/day	D1,D8,D15,D22 D1-D28	Cycle length: 28 days Maintenance part 1結束後再維持1年
GRAALL 2003 ***No CNS involvement***	TIT Cranial irradiation(18cGy)	Induction part 1 Bloc Endoxan Late intensification Before maintenance	D1, D8 D1 D1	TIT 共6次 要和Mercaptopurine同時服用
GRAALL 2003 ***CNS involvement***	TIT Cranial irradiation(15cGy) Cranial irradiation(24cGy)	Induction part 1+2 Bloc 1 Bloc 2 Bloc 3, 6 Before HSCT Before maintenance (if no HSCT)	BIW (共8次) 2次 2次 各1次	TIT 共14次 要和Mercaptopurine同時服用

Hyper CVAD (Cycle 1,3,5,7) Course A	Cyclophosphamide Vincristine Doxorubicin Dexamethasone	300 mg/m^2 (q12h x 6 dose) 2 mg 50 mg/m^2 40 mg/day	D1-D3 D4, D11 D4 D1-D4	(Age > 40; Ph+, 合併 TKI)
Hyper CVAD (Cycle 2,4,6,8) Course B	Methotrexate Cytarabine Leucovorin Methylprednisolone	1000 mg/m^2 IVF 24 hours 3000 mg/m^2 (BID x 4 dose) 100 mg (q6h) 40 mg BID (before Ara-C)	D1 D2-D3 D3- D2-D3	Until MTX < 0.1μmol/L
Hyper CVAD (maintenance)	6-mercaptopurine Methotrexate Vincristine Prednisone	50 mg PO 20 mg/m^2 PO 2 mg IV 200 mg PO	TID QW QM QD	用 5M
CALGB 8811 (Induction)	Cyclophosphamide Doxorubicin Vincristine L-asparaginase Prednisolone G-CSF	1200 mg/m^2 30 mg/m^2 2 mg 6000 IU/m^2 60 mg/m^2 /day 5 μg/kg/day	D1 D1-D3 D1, D8, D15, D22 D5, D8, D11, D15, D18, D22 D1-D22 From D5	(Age > 40; Ph-)
HOP (or CHOP)	(Cyclophosphamide) Doxorubicin Vincristine Prednisolone	1200 mg/m^2 30 mg/m^2 2 mg 40 mg/m^2 , BID	D1 D1-D3 D1, D8, D15 D1-D21	
HD MTX-Ara-C	Methotrexate Ara-C	200 mg/m^2, then 800 mg/m^2 3000 mg/m^2 (q12h，共4 dose)	D1 D2-D4	
N3HDAC	Mitoxantrone Ara-C	12 mg/m^2/day 2000 mg/m^2 (q12h，共8 dose)	D1-D3 D1-D5	

Inotuzumab	Inotuzumab	0.8 mg/m^2 day 0.5 mg/m^2 day 0.5 mg/m^2 day	D1 D8 D15	Pre-medication - Rinderon 1 amp - Acetaminophen x 1 - Vena 1 amp
Chronic Lymphocytic Leukemia (CLL)				
F3C3	Fludarabine Cyclophosphamide	30 mg/m^2 250 mg/m^2	D1-D3 D1-D3	
F3C3M1	Fludarabine Cyclophosphamide Mitoxantrone	30 mg/m^2 250 mg/m^2 6 mg/m^2	D1-D3 D1-D3 D1	
R-F	Fludarabine Rituximab	25 mg/m^2 375 mg/m^2	D1-D5 D1, D4 (C1); D1(C2-6)	
R-FC	Fludarabine Cyclophosphamide Rituximab	25 mg/m^2 200 mg/m^2 375 mg/m^2	D2-D4 D2-D4 D1	
Plasma cell myeloma				
TD **(cycle length: 28 days)**	Thalidomide Dexamethasone	200 mg/day 40 mg/day	D1-D21 D1,8,15,22	Thalidomide in C1: 100mg(D1-D14), 200mg(D15-21) Dexa 20mg if Age > 75

VTD (cycle length: 28 days)	Bortezomib Thalidomide Dexamethasone	1.3 mg/m^2 SC 200 mg/day 40 mg/day	D1,4,8,11 D1-D21 D1,8,15,22	Thalidomide in C1: 100mg(D1-D14), 200mg(D15-21) Dexa 20mg if Age > 75
VRD classic	Bortezomib Lenalidomide Dexamethasone	1.3 mg/m^2 SC 25 mg/day 20 mg/day	D1,4,8,11 D1-D14 D1,2,4,5,8,9,11,12	Cycle length: 21D Br J Haematol . 2022 Oct;199(2):190-204
VRD lite	Bortezomib Lenalidomide Dexamethasone	1.3 mg/m^2 SC 15 mg/day 20 mg/day	D1,8,15,22 D1-D21 D1,2,8,9,15,16,22,23	Cycle length: 35D Br J Haematol . 2022 Oct;199(2):190-204
VRD premium lite	Bortezomib Lenalidomide Dexamethasone	1.3 mg/m^2 SC 15-25 mg/day 20 mg/day	D1,8,15,22 D1-D21 D1,2,8,9,15,16,22,23	Cycle length: 28D Br J Haematol . 2022 Oct;199(2):190-204
VRD ultra lite	Bortezomib Lenalidomide Dexamethasone	1.3 mg/m^2 SC 15 mg/day 20 mg/day	D1,8,15 D1-D21 D1,2,8,9,15,16	Cycle length: 28-35D Br J Haematol . 2022 Oct;199(2):190-204
VCD (cycle length: 28 days)	Bortezomib Cyclophosphamide Dexamethasone	1.3 mg/m^2 SC or IV 300 mg/m^2 40 mg/day	D1,4,8,11 D1,8,15,22 D1,8,15,22	Velcade: SC較不會neuropathy Velcade 可改1.7 mg/m^2 SC D1,8,15 Cyclo可改100mg QD x 4 days Dexa 20mg if Age > 75
VAD	Vincristine Doxorubicin Dexamethasone	0.4 mg 9 mg/m^2 40 mg/day	D1-D4 D1-D4 D1-D4	Dexa 20mg if Age > 75
DECP	Dexamethasone Etoposide Cyclophosphamide Cisplatin	40 mg/day 40 mg/m^2 /day 400 mg/m^2 /day 10 mg/m^2 /day	D1-D4 D1-D4 D1-D4 D1-D4	

VTD-PACE *CVC	Bortezomib Thalidomide Dexamethasone Cisplatin Doxorubicin Cyclophosphamide Etoposide	1.3 mg/m^2 SC(~1.75mg) 50-100 mg/day 40 mg/day 10 mg/m^2 (HD患者, 50% dose post-HD) 10 mg/m^2 400 mg/m^2(HD患者, 50% dose post-HD) 40 mg/m^2(HD患者, 50% dose post-HD)	D1,4,8,11 D1-D28 D1-D4 D1-D4 D1-D4 D1-D4 D1-D4	D1,4和D8,D11共用1支 Continuously 24hrs 24hrs
HD-Melphalan ASCT	Melphalan	100 mg/m^2	D-3, D-2	
MP (Cycle length: 28 days)	Melphalan Prednisone	6-9 mg/m^2/day 60 mg/m^2 /day	D1-D7 D1-D4	D7-D14要抽血調藥至WBC約3000 Cycle length: 28 days
MPT	Melphalan Prednisone Thalidomide	0.25 mg/kg 2 mg/kg 200 mg	D1-D4 D1-D4 D1-D42	Cycle length: 42 days. Up to **12** cycles. N Engl J Med 2014;371:906-17.
KRd	Carfilzomib Lenalidomide Dexamethasone	20 mg/m^2 (C1D1-2), then 27mg/m^2 25mg 40mg	D1,2,8,9,15,16 D1-21 D1,8,15,22	Cycle length: 28 days
Gem/Bu/Mel ASCT for MM	Gemcitabine Busulfan Melphalan	75(loading)+1800 mg/m^2 QD 100 mg/m^2 QD 60 mg/m^2 QD	D-8, D-3 D-8 - D-5 D-3, D-2	Gem: 10 mg/m^2/min Blood 2013

2017 ESMO MM guidelines

Table 6. Major treatment regimens in multiple myeloma

Regimen	Usual dosing schedule
Front-line:	
Bortezomib/melphalan/prednisone (VMP) [11]	Bortezomib 1.3 mg/m^2 subcutaneously days 1, 8, 15, 22; melphalan 9 mg/m^2 orally days 1–4; prednisone 60 mg/m^2 orally days 1–4; repeated every 35 days
Lenalidomide/low-dose dexamethasone (Rd) [12]	Lenalidomide 25 mg orally days 1–21; dexamethasone 40 mg orally days 1, 8, 15, 22; repeated every 28 days
Melphalan/prednisone/thalidomide (MPT) [13]	Melphalan 0.25 mg/kg orally days 1–4 (use 0.20 mg/kg/day orally days 1–4 in patients over the age of 75); prednisone 2 mg/kg orally days 1–4; thalidomide 100–200 mg orally days 1–28 (use 100 mg dose in patients >75); repeated every 6 weeks
Bortezomib/cyclophosphamide/dexamethasone (VCD) [14]	Cyclophosphamide 300 mg/m^2 orally days 1, 8, 15 and 22; bortezomib 1.3 mg/m^2 i.v. on days 1, 8, 15, 22; dexamethasone 40 mg orally on days 1, 8, 15, 22; repeated every 4 weeks
Bortezomib/thalidomide/dexamethasone (VTD) [14]	Bortezomib 1.3 mg/m^2 subcutaneously days 1, 8, 15, 22; thalidomide 100–200 mg orally days 1–21; dexamethasone 20 mg on day of and day after bortezomib (or 40 mg days 1, 8, 15, 22); repeated every 4 weeks × 4 cycles as pre-transplant induction therapy
Bortezomib/lenalidomide/dexamethasone (VRd) [14]	Bortezomib 1.3 mg/m^2 subcutaneously days 1, 8, 15; lenalidomide 25 mg orally days 1–14; dexamethasone 20 mg on day of and day after bortezomib (or 40 mg days 1, 8, 15, 22); repeated every 3 weeks
Relapse/refractory disease:	
Carfilzomib/lenalidomide/dexamethasone (KRd) [24, 32]	Carfilzomib 20 mg/m^2 (cycle 1) and 27 mg/m^2 (subsequent cycles) i.v. on days 1, 2, 8, 9, 15, 16; lenalidomide 25 mg orally days 1–21; dexamethasone 40 mg on days 1, 8, 15, 22; 28-day cycles
Bortezomib/dexamethasone/panobinostat (VD-Pano) [31]	Bortezomib 1.3 mg/m^2 subcutaneously days 1, 8, 15, 22; dexamethasone 20 mg on day of and day after bortezomib; panobinostat 20 mg orally days 1, 3, 5 week 1 and 2; repeated every 3 weeks (cycles 1–8)
Carfilzomib/dexamethasone (Kd) [33]	Carfilzomib 56 mg/m^2 i.v. days 1, 2, 8, 9, 15, 16 (20 mg/m^2 days 1, 2, cycle 1 only); dexamethasone 20 mg days 1, 2, 8, 9, 15, 16, 22, 23; 28-day cycles
Lenalidomide/dexamethasone/elotuzumab (Rd-Elo) [34]	Lenalidomide 25 mg orally days 1–21; dexamethasone 40 mg weekly; elotuzumab 10 mg/kg i.v. weekly cycle 1 and 2, every other week cycles 3+; repeated every 28 days
Lenalidomide/dexamethasone/ixazomib (IRd) [35]	Lenalidomide 25 mg orally days 1–21; dexamethasone orally 40 mg days 1, 8, 15, 22; ixazomib 4 mg orally days 1, 8, 15; repeated every 28 days
Bortezomib/dexamethasone/daratumumab (DVd) [38]	Bortezomib 1.3 mg/m^2 subcutaneously days 1, 4, 8, 11 (cycles 1–8); dexamethasone 20 mg orally days 1, 2, 4, 5, 8, 9, 11, 12 (cycles 1–8); daratumumab 16 mg/kg i.v. every week (cycles 1–3), every 3 weeks (cycles 4–8), every 4 weeks (cycles 9+); cycles 1–8: repeated every 21 days; cycles 9+: repeated every 28 days
Lenalidomide/dexamethasone/daratumumab (DRd) [39]	Lenalidomide 25 mg orally days 1–21; dexamethasone 40 mg orally weekly; daratumumab 16 mg/kg i.v. weekly (cycles 1-2), every other week (cycles 3-6), every 4 weeks (cycles 7+)

Maintenance (velcade based)	Bortezomib Thalidomide	1.3 mg/m^2 100 mg	D1,4,8,11 QD	Cycle length: 3 months
	Bortezomib Thalidomide	1.3 mg/m^2 50 mg	Q2W QD	Up to 2 years
Maintenance (lenalidomide based)	Lenalidomide	10 mg	D1-D21 (也有人QD吃到PD)	Cycle length: 21 days Median PFS 26.7 months (+6.7 months)

Maintenance (Following ASCT)	Ixazomib	3 mg (C1-C4) or 4 mg (C5-, if tolerate 3 mg)	D1,8,15	Cycle length: 28 days Tourmaline-MM3
Aplastic anemia				
CsA + rATG (台大用法, 與 NEJM 2011不同)	Rabbit ATG Methylprednisolone Cyclosporine Methylprednisolone G-CSF	2.5 mg/kg QD 5.0 mg/kg QD 2.5 mg/kg BID 2.5 mg/kg QD 5.0 mcg/kg QN	D1-D5 D1-D5 D6-D90 D6-D10 D6-	Steroid D11後開始 taper, D30 DC
CsA + rATG (N Engl J Med 2011;365:430-8)	Rabbit ATG Cyclosporine	3.5 mg/kg QD 5 mg/kg Q12H	D1-D5 D1-D180	CsA需測濃度維持在200-400 ng/mL, 在6M停藥。aerosolized pentamidine for PJP prophylaxis; valtrex for HSV prevention
Bone Marrow Transplant (BMT)				
BEAM ASCT for lymphoma	BCNU Etoposide Ara-C Melphalan	300 mg/m^2 QD 200 mg/m^2 QD 200 mg/m^2 BID 140 mg/m^2 QD	D-6 D-5-D-2 D-5-D-2 D-1	
Gem/Bu/Mel ASCT for HL	Gemcitabine Busulfan Melphalan *Phenytoin* *Dexamethasone*	75(loading)+1800 mg/m^2 QD 100 mg/m^2 QD 60 mg/m^2 QD 300-600 mg/day 8 mg BID	D-8, D-3 D-8 - D-5 D-3, D-2 D-9 - D-4 D-9 - D-2	Gem: 10 mg/m^2/min Avoid: acetaminophen, metronidazole(會增加busulfan濃度), azoles(增加phenytoin濃度, 減少voriconazole濃度), from D-10 - D-1
Prevention of post-transplant relapse				
Post-transplant azacitidine (RICAZA trial)	Azacitidine	36 mg/m^2 QD SC (24 mg/m^2 if grade III-IV hematological toxicity)	D1-D5	Cycle length: 28 days Total 12 cycles Start since ANC > 1000, Plt > 50k, (median day 54) Relapse hazard ratio: 0.3

Peripheral blood stem cell mobilization (PBSC-mobilization)				
Modified IVE (I劑量⅔)	Ifosfamide Etoposide (VP-16) Epirubicin Mesna Mesna Mesna Keppra G-CSF	3 g/m^2 QD cIF 100-200 mg/m^2 IF 2 hours 50 mg/m^2 IF 30 mins 1.8 g/m^2 IF 15 mins 3.0 g/m^2 cIF 5.4 g/m^2 IF 12 hours 500 mg BID 5 ug/kg	D1-D2 D1-D3 D1 D1 (before Ifos) D1-D2 D3 (after Ifos) D0 - D8 D5-	200 mg/m^2 if no CR CD34 monitoring since D14-20 (after WBC > 5 k/uL) J Clin Exp Hematop. 2016;56(1):50-4
BED	Bendamustine Etoposide Betamethasone G-CSF	120 mg/m^2 200 mg/m^2 32 mg 10 mcg/kg/d sc	D1, D2 D1-D3 D1-D4 D5-	Blood Res 2018;53:223-226
Myelodysplastic syndrome (MDS)				
	Azacitidine	75 mg/m^2 SC	D1-D7	Q4WK
	Decitabine	15 mg/m^2 (q8h, 共 9 dose)	D1-D3	Q6WK